Back to top
more

Adaptimmune Therapeutics (ADAP)

(Delayed Data from NSDQ)

$1.08 USD

1.08
1,162,345

+0.02 (1.42%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $1.08 +0.01 (0.47%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adaptimmune (ADAP) Down on End of Collaboration With Roche

by Zacks Equity Research

Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

by Zacks Equity Research

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $1.20, representing a -1.24% change from its previous close.

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

by Zacks Equity Research

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND

by Zacks Equity Research

Adaptimmune (ADAP) shares rise as GSK transfers IND for letetresgene autoluecel (lete-cel), which is being developed for treating synovial sarcoma and myxoid/round cell liposarcoma.

Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Adaptimmune Therapeutics PLC (ADAP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Adaptimmune Therapeutics PLC (ADAP) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.60, representing a +1.5% change from its previous close.

Adaptimmune Therapeutics PLC (ADAP) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

The latest trading day saw Adaptimmune Therapeutics PLC (ADAP) settling at $0.55, representing a -1.79% change from its previous close.

Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.

Arcturus Therapeutics (ARCT) Surges 15.0%: Is This an Indication of Further Gains?

by Zacks Equity Research

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Liminal (LMNL) Up 40% on Buyout Offer From Majority Shareholder

by Zacks Equity Research

If the minority shareholders of Liminal BioSciences (LMNL) accept the buyout offer, they will receive $8.50 per share. This offer is a dollar more than the initial proposal received by management in April.

Sanghamitra Saha headshot

Buy 5 Top-Ranked Stocks With Rising P/E in July

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).

Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date

by Zacks Equity Research

Alnylam (ALNY) reports that the FDA has set Sep 13, 2023, as the day for the meeting of the Advisory Committee to review its sNDA application for patisiran in treating the cardiomyopathy of ATTR amyloidosis.

Kintara (KTRA) Rises 41% on $2M Grant for Breast Cancer Therapy

by Zacks Equity Research

Kintara (KTRA) receives a $2 million grant from the National Institutes of Health to develop its breast cancer treatment candidate, REM-001. The stock surges 41%.

Liquidia (LQDA) Up on Deal With Pharmosa to Co-Develop PH Drug

by Zacks Equity Research

Liquidia (LQDA) signs an exclusive licensing agreement with Pharmosa to jointly develop and commercialize PAH and PH-ILD treatment candidate, L606, in North America. Shares of the company rise 11%.

Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7%

by Zacks Equity Research

Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.

Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall

by Zacks Equity Research

Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.

AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval

by Zacks Equity Research

AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.

Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data

by Zacks Equity Research

Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.

Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal

by Zacks Equity Research

Horizon (HZNP) announces positive top-line results from its phase III study evaluating Tepezza for treating Thyroid Eye Disease with high disease activity in Japan.

uniQure (QURE) Falls on Mixed Huntington's Disease Study Results

by Zacks Equity Research

uniQure (QURE) stock declines after the company announces mixed results from its biomarkers analysis in the early-to-mid-stage study of AMT-130 in Huntington's disease.

Amgen's (AMGN) Blincyto sBLA Gets FDA Nod in Treating Leukemia

by Zacks Equity Research

Amgen (AMGN) announces full approval of its sBLA for Blincyto as an immune-oncology therapy for treating adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia.

Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug

by Zacks Equity Research

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

GSK Announces Extension of FDA Review for Rare Blood Therapy

by Zacks Equity Research

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study

by Zacks Equity Research

Iovance (IOVA) announces randomizing the first patient in the TILVANCE-301 study evaluating the safety and efficacy of its lifileucel/Keytruda combo therapy in frontline advanced melanoma patients.

Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall

by Zacks Equity Research

Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.